Successful treatment of recurrent *Helicobacter fennelliae* bacteraemia by selective digestive decontamination with kanamycin in a lung cancer patient receiving chemotherapy

Yoshihiro Fujiya, Maki Nagamatsu, Junko Tomida, Yoshiaki Kawamura, Kei Yamamoto, Momoko Mawatari, Satoshi Kutsuna, Nozomi Takeshita, Kayoko Hayakawa, Shuzo Kanagawa, Kazuhisa Mezaki, Masao Hashimoto, Satoru Ishii and Norio Ohmagari

Correspondence
Yoshihiro Fujiya
yfujiya@niid.go.jp

Introduction: *Helicobacter fennelliae* is an enterohepatic *Helicobacter* species causing bacteraemia in immunocompromised hosts. Only a few cases of recurrent *H. fennelliae* bacteraemia have been reported in Japan and there are no guidelines regarding antimicrobial treatment for *H. fennelliae* infection.

Case presentation: *H. fennelliae* bacteraemia was observed in a patient receiving platinum-based chemotherapy for lung cancer. To prevent recurrence, the patient received antibiotic therapy with cefepime, amoxicillin and doxycycline for 6 weeks, which is similar to the therapy for *Helicobacter cinaedi* bacteraemia. Bacteraemia recurred despite the long-term antibiotic therapy. We hypothesized that the *H. fennelliae* bacteraemia originated from endogenous infection in the intestinal tract due to the long-term damage of the enteric mucosa by platinum-based drugs and performed selective digestive decontamination (SDD) with kanamycin. Bacteraemia did not recur after SDD.

Conclusion: Our observations indicate that clinicians should be aware of possible recurrent *H. fennelliae* bacteraemia, which could be effectively prevented by SDD with kanamycin.

Keywords: recurrent bacteremia, lung cancer, chemotherapy; *Helicobacter fennelliae*; selective digestive decontamination, kanamycin.

Introduction

*Helicobacter cinaedi* and *Helicobacter fennelliae* are spiral-shaped Gram-negative rods that are enterohpatic *Helicobacter* species; they inhabit the colons of humans and animals, and cause bacteraemia in immunocompromised hosts, especially in patients with human immunodeficiency virus or haematological malignancies (Kemper et al., 1993; Kiehlbauch et al., 1995; Ng et al., 1987; Hsueh et al., 1999; Rimbara et al., 2013a, b; Saito et al., 2016). *H. cinaedi* and *H. fennelliae* also cause bacteraemia in patients with chronic renal failure, autoimmune diseases and solid organ cancers (Nishine et al., 2007; Matsumoto et al., 2007; Rimbara et al., 2013b; Saito et al., 2016). There are several reports of recurrent *H. cinaedi* bacteraemia in immunocompromised hosts (Sullivan et al., 1997; Mammen et al., 1995; Kikuchi et al., 2012; Uçkay et al., 2006), which is treated with prolonged antibiotic therapy to prevent further recurrence (Kiehlbauch et al., 1994; Tee et al., 1996; Sullivan et al., 1997). However, only a few cases of recurrent *H. fennelliae* bacteraemia have been reported in Japan (Saito et al., 2016), and there are no guidelines regarding the choice or duration of

Abbreviations: CBDCA, carboplatin; GI, gastrointestinal; PEM, pemetrexed; SDD, selective digestive decontamination.
antimicrobial treatment and prevention of recurrence for *H. fennelliae* infection. Here, we describe a case of recurrent *H. fennelliae* bacteraemia, which occurred in a patient receiving platinum-based chemotherapy for solid organ cancer. The recurrence of *H. fennelliae* bacteraemia in this case was successfully prevented by selective digestive decontamination (SDD) with oral kanamycin.

**Case report**

A 73-year-old man suffering from advanced lung adenocarcinoma with multiple metastases was admitted to our hospital in Shinjuku-ku, Tokyo, for a third cycle of chemotherapy. His lung adenocarcinoma diagnosed 8 years previously had gradually progressed despite surgical treatment, chemotherapy and radiation therapy. He also had a medical history of thyroid papillary carcinoma treated by thyroidectomy 7 years previously. The patient had received two cycles of carboplatin/pemetrexed (CBDCA/PEM) therapy within the 4 months prior to this admission.

On hospital day 2, 43 days after the second cycle of chemotherapy, the patient developed a fever (38.3 °C); however, no other symptoms, such as shaking chills, diarrhoea, abdominal pain or extremity pain, were observed. His physical parameters were almost normal. Laboratory examinations showed a white blood cell count of 8640 cells µl⁻¹, a neutrophil count of 6790 cells µl⁻¹ and a C-reactive protein level of 16.2 mg dl⁻¹, indicating a strong inflammatory response.

**Fig. 1.** Phylogenetic tree based on the GyrA protein sequences showing the position of our two isolates (HF-1 and HF-2) within the genus *Helicobacter*. GenBank/EMBL/DDBJ accession numbers and type strains are indicated. The numbers at the branching points are bootstrap percentages (based on 1000 replications). The evolutionally distances were computed using the Kimura empirical model, and the phylogenetic tree was constructed using the NJplot software. The bar represents 1 inferred amino acid substitution per 100 amino acids.
response without neutropenia. Chest X-ray findings were the same as in previous tests. The patient was treated empirically with ampicillin/sulbactam (3 g twice a day) for 2 days without clinical improvement, and then with cefepime (2 g twice a day), after which the fever gradually subsided.

After the initiation of ampicillin/sulbactam therapy, two sets of aerobic and anaerobic blood cultures were performed using BACTEC Plus Aerobic/F culture vials and BACTEC Plus Anaerobic/F culture vials (Becton, Dickinson), respectively. On hospital day 7, one of the two aerobic cultures became positive after 6 days of incubation in BACTEC 9240 medium (Becton, Dickinson), whereas both anaerobic cultures remained negative. Gram staining of the positive culture revealed spiral-shaped Gram-negative rods. Subsequent subculturing on Nissui sheep blood agar plates and Nissui modified Skirrow’s medium EX plates (Nissui Pharmaceutical) revealed thin film-forming colonies and scanty transparent colonies, respectively, after 7 days of incubation at 35°C in a microaerobic atmosphere (6–12 % O₂, 5–8 % CO₂). H. cinaedi was suspected based on the colony characteristics and the biochemical properties of the isolate were tested by the API Campy system (bioMérieux).

The isolate was initially identified as H. fennelliae (microcode 4401064) with a relatively low probability level of 80.2 %. However, the biochemical characteristics of nitrate reduction, alkaline phosphatase production and esterase activity were different from those of H. cinaedi. To confirm the identification, the gyrA gene of the isolate was sequenced (2450 bp) and the deduced protein sequence (811 residues) used to determine the phylogenetic relationship with the GyrA protein of H. fennelliae CCUG 18820T, whose sequence was obtained from a public database (Ménard et al., 2016; Kawamura et al., 2016). In the phylogenetic analysis based on GyrA sequences, the isolate (HF-1; accession no. LC186926) was identified as H. fennelliae (Fig. 1). Antimicrobial susceptibility was determined by the agar dilution method (Rimbara et al., 2012) Our experiments revealed low MICs of ampicillin, cefepime and doxycycline for our H. fennelliae isolate; however, the MIC of ciprofloxacin was much higher than that for H. fennelliae CCUG 18820T (Table 1), which is consistent with previous findings (Rimbara et al., 2013b).

The isolate was initially identified as H. fennelliae (microcode 4401064) with a relatively low probability level of 80.2 %. However, the biochemical characteristics of nitrate reduction, alkaline phosphatase production and esterase activity were different from those of H. cinaedi. To confirm the identification, the gyrA gene of the isolate was sequenced (2450 bp) and the deduced protein sequence (811 residues) used to determine the phylogenetic relationship with the GyrA protein of H. fennelliae CCUG 18820T, whose sequence was obtained from a public database (Ménard et al., 2016; Kawamura et al., 2016). In the phylogenetic analysis based on GyrA sequences, the isolate (HF-1; accession no. LC186926) was identified as H. fennelliae (Fig. 1). Antimicrobial susceptibility was determined by the agar dilution method (Rimbara et al., 2012) Our experiments revealed low MICs of ampicillin, cefepime and doxycycline for our H. fennelliae isolate; however, the MIC of ciprofloxacin was much higher than that for H. fennelliae CCUG 18820T (Table 1), which is consistent with previous findings (Rimbara et al., 2013b).

The patient was treated with cefepime for 15 days, and then with the oral antibiotics doxycycline (100 mg twice a day) and amoxicillin (500 mg three times a day) for 24 days. The long-term antibiotic therapy we used was similar to that used for H. cinaedi. The patient received the third cycle of chemotherapy on hospital day 15 and was discharged on hospital day 21.

After 6 weeks of oral antibiotic therapy, the patient was admitted again for a fourth cycle of CBDDA/PEM therapy. On day 7 after chemotherapy, he showed a high-grade fever (39.8°C) and malaise with no other symptoms. Laboratory tests revealed no neutropenia. H. fennelliae bacteraemia was considered, and the patient was treated empirically with

| MIC (µg ml⁻¹) of: | H. fennelliae isolate | Ampicillin | Amoxicillin | Cefepime | Imipenem | Kanamycin | Gentamicin | Chloramphenicol | Clindamycin | Doxycycline | Minocycline |
|------------------|-----------------------|------------|-------------|-----------|-----------|-----------|------------|----------------|-------------|-------------|-------------|
| HF-1             | 0.5                   | NA         | 0.031       | 0.25      | 0.5       | 0.25      | 0.5        | 0.25           | 0.5         | 0.25        | 0.5         |
| HF-2             | 0.5                   | NA         | 0.031       | 0.25      | 0.5       | 0.25      | 0.5        | 0.25           | 0.5         | 0.25        | 0.5         |
| CCUG 18820T      | ND                    | ND         | ND          | ND        | ND        | ND        | ND         | ND             | ND          | ND          | ND          |
H. fennelliae bacteremia recurrent in spite of the long-term oral antibiotic therapy. The patient was still being treated with CBDBCA/PEM and was at risk of recurrence. We assumed that the primary source of blood infection was the gastrointestinal (GI) tract, which is known as a common reservoir for H. cinaedi (Imafuku et al., 2016; Uçkay et al., 2006), and prescribed SDD with oral kanamycin monosulfate (500 mg four times a day) for 2 weeks. The patient did not have any further episodes of H. fennelliae bacteremia during chemotherapy after completing the SDD.

Discussion

Here, we report a case of recurrent H. fennelliae bacteremia during platinum-based chemotherapy. Based on the clinical course observed in the patient, we can draw three important conclusions. First, H. fennelliae bacteremia could recur during platinum-based anticancer chemotherapy. Our patient had advanced lung adenocarcinoma, progressing despite chemotherapy. He developed a fever without neutropenia or any other symptoms 43 days after the second cycle of chemotherapy. The portal of H. fennelliae entry and the cause of bacteremia episodes in our case were unknown. It has been reported that H. fennelliae could be recovered from stool cultures (Burnens et al., 1993; Smuts & Lastovica, 2011). CBDBCA is a platinum-based anticancer chemotherapeutic agent, which sometimes causes chemotherapy-induced mucositis in the GI tract. In some cases, mucosal inflammation can persist for a long time after chemotherapy because of GI dysfunction due to enteric neuropathy associated with the platinum-based agents (Stojanovska et al., 2015). Therefore, we assumed that the H. fennelliae bacteremia in our case originated from endogenous infection in the GI tract due to damage of the enteric mucosa caused by chemotherapy, and that persisting mucosal damage could result in the recurrence of bacteremia.

Second, recurrent H. fennelliae bacteremia could be prevented by SDD. We chose cefepime, amoxicillin and doxycycline for the treatment based on previous reports (Rimbara et al., 2013b; Kiehlbauch et al., 1995), and the isolate demonstrated high sensitivity to these antibiotics as evidenced by low MICs (Table 1). It should be noted that the MIC of cefepime for H. fennelliae has not been reported previously and that cefepime was clinically effective for our patient. However, H. fennelliae bacteremia recurrent despite a 6 week antibiotic therapy. Given that Helicobacter spp. had not been isolated in specimens from other patients in the same ward either before or after our patient’s admission, we considered it to be a recurrence rather than nosocomial infection. Recurrent bacteremia caused by ‘Helicobacter rappini’ (now classified as Helicobacter bilis) after antibiotic therapy has been reported in a patient with X-linked (Bruton’s) agammaglobulinaemia. In addition, it was reported that in a case of recurrent H. cinaedi bacteremia, SDD with oral kanamycin monosulfate could prevent recurrence (Imafuku et al., 2016). Given that the MICs of aminoglycosides for H. fennelliae are low (Kiehlbauch et al., 1995; Rimbara et al., 2013b; Ng et al., 1987) and that the MIC of kanamycin for our isolate was 0.5 µg ml⁻¹, we prescribed oral kanamycin. Following SDD, no side effects, including renal dysfunction, were observed and bacteremia did not recur despite repeated courses of chemotherapy. As kanamycin is rarely absorbed from the intestinal tract (Hewitt & Finegold, 1958), this observation also indicates that the infection originated from the GI system. Our results suggest that SDD with oral kanamycin can be used to prevent the recurrence of H. fennelliae bacteremia. However, this is, to the best of our knowledge, the first case report of SDD used to treat recurrent H. fennelliae bacteremia and large-scale studies are required to comprehensively investigate the application of kanamycin for SDD in such situations.

Third, fluoroquinolones may be clinically less effective for H. fennelliae infection. No standardized antimicrobial susceptibility tests are currently available for H. cinaedi and H. fennelliae. A recent study has examined a broth microdilution method, which revealed high MICs of fluoroquinolones for H. cinaedi isolated in Japan (Tomida et al., 2013). Although ciprofloxacin demonstrated low MICs for H. fennelliae CCUG 18820T and another previously described isolate (Hsueh et al., 1999), Rimbara et al. (2013b) have reported high MICs of ciprofloxacin for Japanese patients infected with H. fennelliae, which is consistent with our case and may be attributed to gene mutations. Although antimicrobial susceptibility breakpoints for H. fennelliae are yet to be determined, our isolates may be considered resistant to ciprofloxacin (Méraud & Lehours, 2007), suggesting that at least in Japanese patients infected with H. fennelliae, fluoroquinolones, including ciprofloxacin, should be avoided.

In conclusion, our report describes a case of recurrent H. fennelliae bacteremia in a patient with solid organ cancer undergoing platinum-based chemotherapy. Our observations indicate that clinicians should be aware of possible recurrent H. fennelliae bacteremia, which could be effectively prevented by SDD with kanamycin.

Acknowledgements

We thank Hideki Araoka, Toranomon Hospital in Tokyo, Japan, for the consultation regarding SDD therapy. This work was supported by grants from the National Center for Global Health and Medicine (25–114 and 26–101). This report is in accordance with the
Declaration of Helsinki (1975, as revised in 2008) and the regulations of the Japanese Ministry of Health, Labour and Welfare.

References

Burnens, A. P., Stanley, J., Schaad, U. B. & Nicolet, J. (1993). Novel campylobacter-like organism resembling *Helicobacter fennelliae* isolated from a boy with gastroenteritis and from dogs. *J Clin Microbiol* 31, 1916–1917.

Hewitt, W. L. & Finegold, S. M. (1958). Laboratory studies with kanamycin. *Ann N Y Acad Sci* 76, 122–128.

Hsueh, P. R., Teng, L. J., Hung, C. C., Chen, Y. C., Yang, P. C., Ho, S. W. & Luh, K. T. (1999). Septic shock due to *Helicobacter fennelliae* in a non-human immunodeficiency virus-infected heterosexual patient. *J Clin Microbiol* 37, 2084–2086.

Imafuku, A., Araoka, H., Tanaka, K., Marui, Y., Sawa, N., Ubara, Y., Takaichi, K., Ishii, Y. & Tomikawa, S. (2016). *Helicobacter cinaedi* bacteremia in four renal transplant patients: clinical features and an important suggestion regarding the route of infection. *Transpl Infect Dis* 18, 132–136.

Kawamura, Y., Tomida, J., Miyoshi-Akiyama, T., Okamoto, T., Narita, M., Hashimoto, K., Cnockaert, M., Vandamme, P., Morita, Y. & other authors (2016). Proposal of *Helicobacter canicola* sp. nov., previously identified as *Helicobacter cinaedi*, isolated from canines. *Syst Appl Microbiol* 39, 307–312.

Kemper, C. A., Mickelsen, P., Morton, A., Walton, B. & Deresinski, S. C. (1993). *Helicobacter* (Campylobacter) fennelliae-like organisms as an important but occult cause of bacteremia in a patient with AIDS. *J Infect* 26, 97–101.

Kiehlbauch, J. A., Tauze, R. V., Baker, C. N. & Wachsmuth, I. K. (1994). *Helicobacter cinaedi*-associated bacteremia and cellulitis in immunocompromised patients. *Ann Intern Med* 121, 90–93.

Kiehlbauch, J. A., Brenner, D. J., Cameron, D. N., Steigerwalt, A. G., Makowski, J. M., Baker, C. N., Patton, C. M. & Wachsmuth, I. K. (1995). Genotypic and phenotypic characterization of *Helicobacter cinaedi* and *Helicobacter fennelliae* strains isolated from humans and animals. *J Clin Microbiol* 33, 2940–2947.

Kikuchi, H., Asako, K., Tansho, S., Ueda, T., Koshio, O., Ubagai, T., Asahara, M., Kawakami, S. & Ono, Y. (2012). Recurrent *Helicobacter cinaedi* cellulitis and bacteremia in a patient with systemic lupus erythematosus. *Intern Med* 51, 3185–3188.

Mammen, M. P., Aronson, N. E., Edenfield, W. J. & Endy, T. P. (1995). Recurrent *Helicobacter cinaedi* bacteremia in a patient infected with human immunodeficiency virus: case report. *Clin Infect Dis* 21, 1055–1056.

Matsumoto, T., Goto, M., Murakami, H., Tanaka, T., Nishiyama, H., Ono, E., Okada, C., Sawabe, E., Yagoshi, M. & other authors (2007). Multicenter study to evaluate bloodstream infection by *Helicobacter cinaedi* in Japan. *J Clin Microbiol* 45, 2853–2857.

Mégraud, F. & Lehours, P. (2007). *Helicobacter pylori* detection and antimicrobial susceptibility testing. *Clin Microbiol Rev* 20, 280–322.

Ménard, A., Buissonnière, A., Prouzet-Mauléon, V., Sifré, E. & Mégraud, F. (2016). The GyrA encoded gene: a pertinent marker for the phylogenetic revision of *Helicobacter* genus. *Syst Appl Microbiol* 39, 77–87.

Ng, V. L., Hadley, W. K., Fennell, C. L., Flores, B. M. & Stamm, W. E. (1987). Successive bacteremias with "Campylobacter cinaedi" and "Campylobacter fennelliae" in a bisexual male. *J Clin Microbiol* 25, 2008–2009.

Nishine, H., Kasai, S., Yoshikawa, M., Otsuka, Y. & Tokuda, H. (2007). [A case of recurrent *Helicobacter cinaedi*-associated bacteremia in a small cell lung cancer patient during chemotherapy]. *Nihon Kokuuki Gakkai Zasshi* 45, 26–30 [in Japanese].

Rimbara, E., Mori, S., Matsu, M., Suzuki, S., Wachino, J., Kawamura, Y., Shen, Z., Fox, J. G. & Shibayama, K. (2012). Molecular epidemiologic analysis and antimicrobial resistance of *Helicobacter cinaedi* isolated from seven hospitals in Japan. *J Clin Microbiol* 50, 2553–2560.

Rimbara, E., Matsu, M., Mori, S., Suzuki, S., Suzuki, M., Kim, H., Sekizuka, T., Kuroda, M. & Shibayama, K. (2013a). Draft genome sequence of *Helicobacter fennelliae* strain MRY12-0050, isolated from a bacteremia patient. *Genome Announc* 1, e00512-13.

Rimbara, E., Mori, S., Kim, H., Matsu, M., Suzuki, S., Takahashi, S., Yamamoto, S., Mukai, M. & Shibayama, K. (2013b). *Helicobacter cinaedi* and *Helicobacter fennelliae* transmission in a hospital from 2008 to 2012. *J Clin Microbiol* 51, 2439–2442.

Saito, S., Tsukahara, M., Ohkus, K. & Kurai, H. (2016). *Helicobacter fennelliae* bacteremia: three case reports and literature review. *Medical* 95, e3556.

Smuts, H. E. & Lastovica, A. J. (2011). Molecular characterization of the 16S rRNA gene of *Helicobacter fennelliae* isolated from stools and blood cultures from paediatric patients in South Africa. *J Pathog* 2011, 217376.

Stojanovska, V., Sakalk, S. & Nurgali, K. (2015). Platinum-based chemotherapy: gastrointestinal immunomodulation and enteric nervous system toxicity. *Am J Physiol Gastrointest Liver Physiol* 308, G223–G232.

Sullivan, A. K., Nelson, M. R., Walsh, J. & Gazzard, B. G. (1997). Recurrent *Helicobacter cinaedi* cellulitis and bacteremia in a patient with HIV Infection. *Int J STD AIDS* 8, 59–60.

Tee, W., Street, A. C., Spelman, D., Munckhof, W. & Milich, A. (1996). *Helicobacter cinaedi* bacteremia: varied clinical manifestations in three homosexual males. *S Afr J Infect Dis* 28, 199–203.

Tomida, J., Oumi, A., Okamoto, T., Morita, Y., Okayama, A., Masawa, N., Hayashi, T., Akaike, T. & Kawamura, Y. (2013). Comparative evaluation of agar dilution and broth microdilution methods for antibiotic susceptibility testing of *Helicobacter cinaedi*. *Microbiol Immunol* 57, 353–358.

Uckay, I., Garbino, J., Dietrich, P. Y., Ninet, B., Rohner, P. & Jacomo, V. (2006). Recurrent bacteremia with *Helicobacter cinaedi*: case report and review of the literature. *BMJ Infect Dis* 6, 86.